Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru

Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis (TB) treatment. We assessed the prevalence of isoniazid and rifampicin mono-resistance, associated risk factors, and the association of mono-resistance on treatment outcomes. A prospective, observational cohort...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	PloS one Ročník 11; číslo 4; s. e0152933
Hlavní autori:	Villegas, Leonela, Otero, Larissa, Sterling, Timothy R., Huaman, Moises A., Van der Stuyft, Patrick, Gotuzzo, Eduardo, Seas, Carlos
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Public Library of Science 05.04.2016 Public Library of Science (PLoS)
Predmet:	Adult Adults Alcoholism Analysis Antibiotics Antitubercular Agents - therapeutic use Biology and Life Sciences Clinical outcomes Confidence intervals Dosage and administration Drug abuse Drug resistance Drug Resistance, Bacterial Drug therapy Drugs Epidemiology Female Health care facilities Human immunodeficiency virus Humans Humboldt, Alexander von (1769-1859) Isoniazid Isoniazid - therapeutic use Laboratories Male Medicine Medicine and Health Sciences Mycobacterium Mycobacterium tuberculosis Observational studies Patient outcomes Patients Peru - epidemiology Prevalence Public health Pulmonary tuberculosis Regression models Resistance factors Rifampin Rifampin - therapeutic use Risk analysis Risk Factors Smear Sputum Statistical analysis Studies Substance abuse treatment Systematic review Treatment outcome Tuberculosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - epidemiology Peru South Africa Belgium United States > US Lima Peru Nashville Tennessee
ISSN:	1932-6203, 1932-6203
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!